The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...

Summer is creeping closer, and for Gilead Sciences that only means one thing: the much-anticipated launch of long-acting HIV ...

Despite steep budget and staffing cuts at the FDA in recent weeks and other headwinds, Gilead CEO Daniel O’Day assured investors that the pharma’s plans and preparations for lenacapavir’s launch ...

The Barchart Brief: Your FREE insider update on the biggest news stories and investing trends, delivered midday TheChart of ...

Gilead’s HIV drug business grew while its Covid drug sales tanked in the first quarter of 2025, as the company recorded the ...

Gilead Sciences' Q1 2025 earnings reveal challenges in oncology and Veklury sales, while HIV therapies remain strong. See why ...

Gilead Sciences has taken a major step ... production and distribution of lenacapavir, its long-acting HIV prevention medication, in 120 high-incidence and resource-limited countries.

The medicine, lenacapavir, made by Gilead Sciences ... given its experience distributing HIV prevention drugs around most of the world.

He was 12 years into his virology research career at Gilead ... HIV treatment was still awaiting approval. Treatment options for people living with HIV at the time were a raft of daily medications ...